Cargando…
Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting
PURPOSE: The purpose of this study was to analyze the therapeutic strategies and estimate the health care resource consumption in patients with psoriatic arthritis (PsA). PATIENTS AND METHODS: An observational retrospective cohort analysis of administrative databases of six Italian Local Health Unit...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348972/ https://www.ncbi.nlm.nih.gov/pubmed/30774314 http://dx.doi.org/10.2147/PPA.S178603 |
_version_ | 1783390203419820032 |
---|---|
author | Degli Esposti, L Perrone, V Sangiorgi, D Alessandrini, D Buda, S Cantini, F Mazzini, E Toma, C De Solda, F |
author_facet | Degli Esposti, L Perrone, V Sangiorgi, D Alessandrini, D Buda, S Cantini, F Mazzini, E Toma, C De Solda, F |
author_sort | Degli Esposti, L |
collection | PubMed |
description | PURPOSE: The purpose of this study was to analyze the therapeutic strategies and estimate the health care resource consumption in patients with psoriatic arthritis (PsA). PATIENTS AND METHODS: An observational retrospective cohort analysis of administrative databases of six Italian Local Health Units was performed. Patients ≥18 years with a hospitalization discharge diagnosis of PsA (International Classification of Diseases, Ninth Revision code: 696.0) or exemption code (045.696.0) for PsA from January 1, 2010 to December 31, 2015 (inclusion period), with at least one prescription of any therapy used for PsA were included. The index date (ID) was the first date matching with at least one of the inclusion criteria during the inclusion period. All patients were followed up after the ID until the end of data availability. Baseline C-reactive protein (CRP) levels (±6 months in relation to the ID) were also analyzed. RESULTS: A total of 2,408 (prevalence 0.83 per 1,000) patients with PsA (male 52%; median age 54 years) were included in the study; patients were already treated for PsA in 42.4% of cases. At 1 year of follow-up, 73% of the patients received one systemic drug, while 22% of patients received two systemic drugs; in addition, our results show an increase in the number of add-on or switches in a longer follow-up period. The utilization of biologic agents was higher among patients with previous PsA treatment, showing a progression of the pathology. Overall, a medium/high level of CRP at baseline was observed among more than half of the overall sample, with slight changes across subgroups in analysis. The average health care costs were €1,966.4 and €13,914 per year for patients treated with conventional systemic therapy and biological agents, respectively. CONCLUSION: A better knowledge of prescription therapeutic scheme and economic burden of PsA could stimulate the rational development of health programs aimed at potentiating services for its management. |
format | Online Article Text |
id | pubmed-6348972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63489722019-02-15 Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting Degli Esposti, L Perrone, V Sangiorgi, D Alessandrini, D Buda, S Cantini, F Mazzini, E Toma, C De Solda, F Patient Prefer Adherence Original Research PURPOSE: The purpose of this study was to analyze the therapeutic strategies and estimate the health care resource consumption in patients with psoriatic arthritis (PsA). PATIENTS AND METHODS: An observational retrospective cohort analysis of administrative databases of six Italian Local Health Units was performed. Patients ≥18 years with a hospitalization discharge diagnosis of PsA (International Classification of Diseases, Ninth Revision code: 696.0) or exemption code (045.696.0) for PsA from January 1, 2010 to December 31, 2015 (inclusion period), with at least one prescription of any therapy used for PsA were included. The index date (ID) was the first date matching with at least one of the inclusion criteria during the inclusion period. All patients were followed up after the ID until the end of data availability. Baseline C-reactive protein (CRP) levels (±6 months in relation to the ID) were also analyzed. RESULTS: A total of 2,408 (prevalence 0.83 per 1,000) patients with PsA (male 52%; median age 54 years) were included in the study; patients were already treated for PsA in 42.4% of cases. At 1 year of follow-up, 73% of the patients received one systemic drug, while 22% of patients received two systemic drugs; in addition, our results show an increase in the number of add-on or switches in a longer follow-up period. The utilization of biologic agents was higher among patients with previous PsA treatment, showing a progression of the pathology. Overall, a medium/high level of CRP at baseline was observed among more than half of the overall sample, with slight changes across subgroups in analysis. The average health care costs were €1,966.4 and €13,914 per year for patients treated with conventional systemic therapy and biological agents, respectively. CONCLUSION: A better knowledge of prescription therapeutic scheme and economic burden of PsA could stimulate the rational development of health programs aimed at potentiating services for its management. Dove Medical Press 2019-01-22 /pmc/articles/PMC6348972/ /pubmed/30774314 http://dx.doi.org/10.2147/PPA.S178603 Text en © 2019 Degli Esposti et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Degli Esposti, L Perrone, V Sangiorgi, D Alessandrini, D Buda, S Cantini, F Mazzini, E Toma, C De Solda, F Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting |
title | Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting |
title_full | Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting |
title_fullStr | Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting |
title_full_unstemmed | Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting |
title_short | Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting |
title_sort | therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an italian setting |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348972/ https://www.ncbi.nlm.nih.gov/pubmed/30774314 http://dx.doi.org/10.2147/PPA.S178603 |
work_keys_str_mv | AT degliespostil therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting AT perronev therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting AT sangiorgid therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting AT alessandrinid therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting AT budas therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting AT cantinif therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting AT mazzinie therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting AT tomac therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting AT desoldaf therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting |